### Our Commitment to Responsible Business & Sustainability

Our ambition is to be a leading corporate citizen, acting with courage, creativity, and discipline to provide equitable benefit to our patients, business, and society. Our strategy for the coming years focuses on four areas aligned with BeiGene's mission, vision and values. These focus areas are supported by key strategic priorities.

Our <u>2023 Responsible Business &</u>
<u>Sustainability Report</u>, published in April 2024, details our efforts in each of these areas and describes recent progress.

#### Advancing Global Health

- Innovative Products
- Patient Access, Engagement & Advocacy

## Empowering Our Colleagues

- Diversity, Equity, Inclusion & Belonging
- Engagement, Well-Being & Volunteerism

### Innovating Sustainably

- Climate & Environmental Impact
- Product Stewardship



# Operating Responsibly

- Integrity, Governance & Risk Management
- Responsible Sourcing





### **Key Achievements in 2023**



- Formalized our approach to global health equity
- Achieved progress in elevating patient insights in our drug development strategy
- Launched The BeiGene
  Foundation, an independent
  501(c)(3) organization, dedicated to
  eliminating barriers to equitable and
  accessible cancer care in
  underrepresented communities
  around the world



- Increased the percentage of women
   holding a position of VP or higher
   from 33% to 38%
- Launched LIFT (Leading Innovation and Future Transformation), a global cross-regional and cross-functional senior leadership program
- Hosted the first global employee
  Development Week
- Launched Be the Change, a global employee volunteer platform, and surpassed 20,000 hours of volunteerism



- Set first quantitative emissions reduction goal
- Laid the groundwork for a **supplier engagement program**, launched in January 2024, to support setting a Scope 3 target by 2025
- Our Enterprise Risk Management (ERM) team integrated climate change into our enterprise-level risk management program



- Launched a third-party risk management program
- Set goal to develop a strategy aligning with the United Nations Global Compact's guidance on human rights by 2025
- Set goal to develop a plan better aligning key privacy performance metrics with Responsible Business & Sustainability practices by 2025



### Goals



- Bring multiple high-quality new molecules from discovery into the clinic on an annual basis
- Continue to seek approvals for our medicines globally
- Spearhead multi-stakeholder solutions that empower patients and disrupt systemic access barriers by 2025



- Maintain colleague engagement scores in 2024 vs 2022
- Reach global gender parity at the VP level and above by 2030
- Achieve a 50% improvement in workforce diversity of underrepresented groups at management levels in the US by 2030
- Continue to address Board diversity
- Engage employees in 10K volunteer hours by the end of 2024, stretch goal of 20K hours



- Reduce Scope 1 and 2 emissions,

   (emissions generated by owned and operated facilities), by 25% per unit of internally manufactured commercial product by 2026 from a 2021 base year
- Set quantitative Scope 3 emissions goal by 2025 by engaging with the most impactful of our raw supplier base
- Develop a product stewardship strategy



- Develop a plan to better align key privacy performance metrics with RB&S practices by 2025
- Develop a strategy to align with the United Nations Global Compact's guidance on human rights by 2025

